Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Conference · 2026-11-12
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
Day three of the 2026 Stiefel Healthcare Conference. We are on the life sciences side with Mettler Toledo International. Happy to have CFO Sean Vidala with us today. Sean, thanks very much for spending some time.
Yeah, hey, thanks, Dan. It was great to see you. It was great to see everybody. Thanks for hosting us today.
Yep, yep. Busy week or last week or so for you guys and for us. You reported earnings on Friday. It was a good quarter. Then we were down in Tampa for your Investor Day. Maybe that's a good place to start. It was the first one in four years. Can you just a little talk about the message there and what you think were the most salient points coming out of that? What do you think we should know as investors and analysts?
Yeah, so I think to me there was a few things that stood out. I mean, I think we covered a lot of ground there. But, you know, the first message is that we've been investing quite a bit in the business over the last few years, you know, and we tried to like really outline that. So it starts with R&D and innovation. You know, we've increased our R&D spending by 32% in the last five years. And, you know, that's led to increasing our value proposition to our customers, but also a lot of new products. If you listened to our quarters over the last couple of years, you might have picked up that we're talking a little bit more about examples of new product introductions. That's, I think, extremely important, and it's been well-received in the market. The second area that we've been investing in is digitalization. This is not a new topic for us. We've been investing in the Blue Ocean program for 20 years. It provides a really strong platform for us internally. You know, if you think about it, one single instance of an IT infrastructure with harmonized global processes. But then that gives you, like, it allows you to automate things, but it also gives you the data, right? And the data that you need to gain the insights. Now that we have new technologies like AI, you know, we can kind of go to that next level. So, we, you know, talked about that. We talked about some of the new growth initiatives that we have introduced in the last few years, like in the service organization, as an example. And the last area that we've been investing in is resilience. Like, you know, most companies around the world, you know, we've, you know, kind of, as we're coming out of COVID, we wanted to have a more resilient supply chain, you know, and so. So as we were thinking about that, we wanted to have more flexibility in that supply chain, and we wanted to be able to be a little bit closer to our customers. And so now with the onset of tariffs, of course, we've had to accelerate a lot of those investments as well, too. But sitting here today, it's nice having a more flexible, agile supply chain. So that was like category number one. Category number two is I feel like even though the algorithm is very much the same as we might have talked about in the past, The number of drivers is much more, you know. So if you think about all the different types of growth drivers that we outlined during the investor day, that's what gets me really excited. You know, there's just a lot of more opportunities to kind of get to roam, if you will. And so we kind of went through each one of those. I'm sure you'll kind of want to dig into some of that so I won't go into too much detail now. But, you know, whether it be, you know, a better mix in the business, whether it's trends in automation and digitalization, whether it's some of these hot segments, there's just a lot of great opportunities in the business, including the unshoring opportunities. And, yeah, and then the last thing is I just think we're, you know, we're just very well positioned for the future. We have really strong return on invested capital, strong free cash flow, and I think we're very much prepared for the future.
Maybe just on the automation and digitization point, because you're right, I mean, that has something that's been a tailwind for you guys. Longer than the AI conversation has been what it is right now. Can you maybe separate out, A, where that trend is accelerating for you, and the idea would be 2027 is a year where you have more of that working for you as an organic growth driver, and then, B, how AI does play into that, and what customers are actually prepared to handle AI capabilities that you might enable?
Yeah, hey, great question, and that third category really is getting to the heart of it, is like being prepared for the future really is about having the right platform to support our customers, whether it be with their AI programs, whether it's their automation needs, their digitalization needs, but also the platform internally, you know, to whether it's how we develop products, how we engage customers, or how we gain more insights and productivity within Mettler Toledo. So as you think about it, like in terms of supporting customers, we have... One of our strengths is that we serve them throughout their value chain. So you think about R&D all the way through production. We have a broad offering of instruments. So we have all these instruments and also sensors that collect information, right? And then on top of that, though, we have the software data layer. So we have WabX software in the laboratories, but we also have industrial terminals in the production environment. And that's really critical because when you have a broad range of instruments and you have one software application to collect all that, It can do it in a very structured way, a validated way, a compliant way that really is impactful for our customers, but it also helps them with their own AI programs, right? And so, or their automation programs, you know, and so like we gave an example that you saw at the investor day of like an example of what an autonomous lab could look like, right? And so, you know, in an autonomous lab, there's a wide range of different types of instruments. Any day, you can do a different combination of different types of instruments. We're pretty fortunate because we have some of the most commonly used instruments in a lab, like whether it be a laboratory balance or a pipette for liquid handling. But then we can enable most of our instruments with LabX, and then we partner with external robotics companies, right? And then so LabX is the tool that communicates with the robot. It enables the workflow automation, but then it's also collecting the data during the process that it can then feed into their AI program. That's just one example. Of course, we're doing a lot of things in the industrial environment. We're doing things in bioprocessing, like with process analytics that you would have seen. But in the end, there's a lot of things that we're doing for our customers to enable their own AI programs. And then the other side of it is, like, how are we using that internally? And I can't remember the full part of your question, but maybe I'll go in that direction, too. It's like we're also using AI internally in terms of how we provide products to the market. So if you think about, like, some of those examples that we had the other day with, like, imaging technologies or, you know, advanced algorithms or whatever, However, there's a lot of things that we can do to add value to our customers with our products. We have embedded AI wizards, as an example, in some of our analytical instruments. The second category is how we're using it to engage customers, you know, with a more digital experience. And then the third category, of course, is how we're leveraging it internally. We have, like, I think, like 5,000 agents at the moment deployed with over 100 use cases through all the different functional areas in the company. And when we do that, of course, there's, you know, productivity involved. But I think, to me, what gets me excited is the insights that we're getting out of the business to be able to innovate faster and ultimately, you know, support our customers.
Yeah. Okay. All right. Let me maybe try and come back to AI at the end, because I think people would like to hear you talk about just how that's going to be a good guy for you. I mean, across the board, but also just for, you know, the two sides of the business. Before we do that, I want to just talk about instrument replacements, which you touched on. At the analyst day, it was, I thought pretty clear that the way that you're thinking about the instrument cycle now is different than it was a year or two ago. Amazingly, we're still talking about this as being like a post, you know, the coming out of the COVID period. How do you see the instrument replacement cycle today or into 2027? When it comes to just sort of accelerating demand and thinking about who might be willing to replace an instrument that wasn't last year or two years ago. And then the corollary to that would just be, are you seeing new sources of instrument demand, just given basically the automation trend that we're talking about here?
Yeah. Good way to end it as well with the question. In terms of replacement demand, we were encouraged last quarter when we started to see categories like analytical instruments pick up, laboratory balances. Think about the instruments that are typically around a QA, QC bench. That's where we started to see in Q2 the business really picking up, and it was nice to see that trend continue into the third quarter. So we kind of, you know, it's hard to tell exactly how much is replacement or not, but we felt like these are the categories that we would see first, and so that was kind of nice to see. So like as we, you know, guide Q4 and we start to think about how we'll start next year, it feels to us like that trend will continue. But when we kind of step back from the whole thing, You know, you think about what was our business pre-COVID? You know, like, what did it take to grow this business? And in the Western markets, it was pretty much customers sticking to their replacement cycle. I mean, 80 to 90 percent of what we did was really customers sticking to their replacement cycle. And so just getting back there is actually a pretty big deal for us. And when we, and then when you kind of like look at the most recent time period, we kind of showed a slide the other day that showed. In 2021, our sales went up 18%, and then in 2022, they went up 12%. And so we kind of like had like a lot of companies, just a lot of extra replacement that was happening, maybe an acceleration of replacement cycle that happened in those two years, which is kind of unique for our space. And then, and then there was kind of like the aftermath here, you know, but now if you think about like, well, what's the average age of an instrument, it tends to be, you know, anywhere from five to 10 years, depending on the use and the environment. We typically say that the average is around seven years, but it can be more or less. But if now you start to do some simple math on that time period, it kind of makes sense, right? Like we might be at the very beginning early of something that might be in that five-year range, but the sweet spot will be more in that probably seven-year kind of range, but could have a tail out to 10 years. Now, of course, some things can last longer, but that's kind of like how we're looking at that. So just that alone should be a meaningful thing. And like you said, in addition to that, we do have new investment opportunities. Our customers investing, I mean, automation and digitalization, I mean, it's clearly an important trend. And maybe coming back to your first question, like, you know, if I look at the parts of our business that are performing the best, they're the products categories that support, directly support our customer automation and digitalization needs. And like when you really go under the covers of like the industrial business, you know, you'd see those categories doing very well. We have a little bit of project topics with some other businesses like last year. We have that tough comp that maybe kind of like makes that not so obvious, but we really have. Very good trends there, and they're global trends, but we also see it in the lab as well, too.
Yeah, and I would also imagine that if you're a lab and you're looking to your left and you're looking to your right and both guys are replacing their instruments with the idea that they need AI enablement, you're likely to do the same thing. Sort of to keep up with the Joneses, I mean, I don't think Mettler-Tudo gets compared to a next-gen sequencing company all that often, but it does seem like this idea where you kind of have to make sure that you're on par with where others are going, even if you weren't thinking about buying that box in the next six months. I mean, would you agree with that, or would you say that, you know, the peer pressure is less than maybe what I'm making it out to be?
I mean, for our customers, you mean?
Yeah, I mean, if everybody else is going to be connected in an AI way, and you feel like you would be at a strategic disadvantage... By not doing so, does that become a motivator for people to kind of get on board with a new system?
I mean, it's like any new technology. I think most of our customers are going to want to understand it. They're going to want to try it. They're going to want to invest in it. And then if they have success, then they're going to double down on it. And I think I would imagine a lot of them, I mean, we can see it with the engagement we have with customers at the moment, that the number of conversations are increasing quite a bit in this area. And I just think, like, for what we do, we're very well positioned for it, given that breadth, given that software layer, et cetera.
Okay, maybe let's just talk about the outlook for 2027, because that was new for the 3Q call, and we certainly got into a little bit of it at the investor day. So the guide for 2027 is 5% local currency. That would put it on par with where 2026 seems like it's pointed. And then by segment, that's lab up high singles, mid singles for industrial, and then food retail would be low single digit. That generally makes sense. I think the part that maybe strikes me as an interesting assumption is just on industrial or in industrial, because product inspection, the outlook is for low to mid singles, and we were at the product inspection facility, and everything looks like it's going really, really well. So, you know, the comps are going to be meaningful. Is that really the basis for the starting point that says, hey, we should think about something maybe lower than mid-singles for 2027 as we sit in 2026?
Yeah, I think we are kind of looking at, like, first of all, in Q4, we have line of sight, right? And it's going to be, you know, I think we grew. I think it was, was it double digit the last two years in a row? I'm looking at Adam here in Q4 for product inspection. And so like, so we're lapping some comps already here in the fourth quarter. So our growth will be most likely pretty muted, you know, in the fourth quarter. As we look to next year, that kind of influences us a little bit just with like, you know, there we are coming off a couple years of higher growth. You know, we are going to be somewhat tied to our customer capital plans here. We acknowledge it's, you know, 70% of the business is food manufacturing, so it's always a little bit difficult to tell, like, how at what pace they're going to invest. But when you step back from it, you know, we've been competing extremely well in maybe arguably a softer market here. I think as we've kind of, like, increased our TAM and really kind of gone after the mid-market more in the last few years, I think that's been very successful. You saw a lot of examples of new innovation there, new innovation that targets that mid-market, but also now coming out with new products at the premium level, like really the highest end of metal detection, x-ray. These are products that are just released. I have to believe that these are going to also help in terms of growth for next year. You could see a little bit the excitement and enthusiasm from our team the other day, and I think the market is also receiving it very well, too. And so I do feel good about our portfolio and our team and our ability to execute. I also think that within food, there's a lot of opportunity that you also heard, too. Right. Like, you know, there are going to be, you know, rethinking of package sizes and, you know, more protein, you know, offerings and stuff that kind of fits a GLP one diet. And all that actually creates a lot of investment as people are rethinking their packaging and their in their production lines. And so I do think that there's good opportunity for us here as well, too. So we're, again, we're probably a little bit more modest, just given some of the comps, but we do have a lot of good things as well. Iron's in the fire, as they say. Yeah, okay.
Okay, and then maybe just touching on China. I mean, China is another area of the business where things are going pretty well. In the first half of the year, it felt like that was the setup for the second half of the year. What has played out the way that you thought it would, and then what is maybe different? And then there's sort of a similar version of a question to the last one, which is, how do you think about next year's growth outlook for China, just given the comp that you'll be dealing with, but also just that you are seeing a lot of the good stuff going on in China in the second half?
Yeah, I mean, I think we started the year kind of with modest expectations, But certainly hoping to see better growth this year. Even during the downturn, I think we've been very consistent with our views on China. We've always viewed this as an attractive end market for us. We are, I think, just very well positioned in the country in terms of the end markets that we focus on. I think they're very well aligned with the strategic priorities in the country, Whether it be the pharmaceutical industry, but also some of the hot segments, like clean energy, which has subcategories like batteries, is a really good example. We have a great footprint there in terms of what we sell in China, we largely make in China, too. I think that's important. And then who we're selling to, about 70% of our business there is sold to private companies within China, with probably 10% to 15% sold to multinationals. So I think that helps us from a sustainability perspective as well as we think about now the year. The thing that I really like at the beginning of the year is we're starting to see early signs of the industrial business recovering, and that's important. Our China business is overweighted to industrial, particularly core industrial. We're actually underweighted on the product inspection side, so this really gets to the heart of production and manufacturing, the economy. You know, and, you know, yes, it's our core segments, so we have some secular exposures, but it's still, like, are they, you know, are people making stuff there?
It sits at the root of the decisions.
Yeah, and so what was nice to me is that I think a few years back when the economy reset, there were pockets of overcapacity in certain industries, right? And what was nice to see is that these industries kind of worked through that. And now they kind of grew back into that. And then we're seeing, I think, more, you know, more organic growth and sustainable growth coming out of it. Now, with that being said, we know that things in China can always change very quickly in either direction. But it's nice to see that we're, you know, kind of going in the right direction at the moment. You know, at the beginning of the year, we I think in Q4 a year ago, we kind of grew for the first time in industrial in a while. We started to talk about that as like a early sign that, you know, You know, things might be moving in the right direction. In Q1... We saw that industrial business grow high single digits, and then for the second half of the year, that industrial business is now growing mid-teens. And then if you think about Lab, Lab has been a little bit of a, kind of a laggard to that. In the first half of the year, it was flattish, maybe down slightly Q1, up slightly Q2. We grew high single digits in Q3, and then in Q4. Our guidance is for mid-teens. So you can kind of see we're really exiting the year with a lot of momentum. I expect that momentum will carry into the beginning of the year. But we're going to start lapping more difficult comps now on the industrial side. And again, again, we were just being a little bit more cautious in how we guide China right now, knowing that things can always change quickly and that. And that we're lapping these comps. But just to be clear, we're not seeing anything today that says, you know, things are going to slow down. Change for the worse. Yeah, I mean, and if you look at how. How businesses are investing in China, they're very much in the strengths of our portfolio. It keeps on coming back to their, they're moving as fast as anybody with automated solutions. They're moving as fast as anybody with digital solutions, and it really plays to the strength of our portfolio. So we do feel very good about this. And with our LRP, we were also, I think, a little bit more modest here and just said, like, hey, it's a long-term thing. You know, we'll be right around corporate average, and we should be fine. But of course, you know, there's a bull case on it as well, too, and we'll see how it plays out.
Yeah, okay. What about the market share environment in China? Do you still see there being good opportunity? I mean, I would imagine that... As China emerges from the funk that it's been in, or the quasi-funk that it's been in, that maybe there are fewer mom-and-pop or regional players, whatever you want to call them, that are just sort of easy targets for Mettler to just sort of... Do what you need to do or do what you like to do. Is that still a dynamic that is going to work for you? I guess how would you count on market share as something to augment just sort of natural organic growth over the next couple of years?
Yeah, I think our market share is relatively similar to our corporate average in China for the most part, but we tend to have a higher relative market share to the number two. The markets tend to be more fragmented there, especially on the industrial side, and that plays well for us. And then, you know, with us having significant R&D capabilities in China, we're able to really compete at maybe not only the mid-market level, but the lower part of mid-market to really make sure we're competing with that segment of the market as well, too. And we've always had different strategies to make sure that we're not taking anything for granted in terms of, like, the competitive environment. And I just feel like, hey, in the end, if you're bringing value to your customer, you know, then that's the key, right? And so, like, we are, like, back to just being in China recently. Like, we had a great trip, tons of energy, but they're just so proud of all the innovation that they're coming out with every year. Like, I mean, it's amazing to see the progress that can be made from one year to the next internally just with innovation topics and time to market on things. And just, and it's actually stuff that we can leverage globally as well, too, in terms of like just that R&D, you know, agility. And so a lot of good things there. So I think we're competing very well. I think you can kind of see it in the numbers. I can't speak necessarily for, you know, all the mom and pops out there. It's always been like that, but I kind of feel like as a company our size, we can continue to invest much more heavily in the things that are really going to move the needle, like This digital solutions and automated solutions, and I think that's the key.
Do you see competitive risk to the reign in business in China from local players? I get that question a lot just when it comes to where are you most vulnerable or where companies in the space most vulnerable to China.
Yeah, the answer is actually no different than a lot of other businesses, right? If we're not differentiated, then that would be a much more difficult situation. But in terms of what we're doing with pipettes and where we play, we're not trying to do everything. We carved out our niche in liquid handling where it's the area where customers really care about quality, they really care about precision, and that's what we're going after. If you start going after a more, like, the universal tip, you know, environment, like, that's going to be much more competitive. That's going to be more price sensitive. But what we do, it's a niche segment, and if I look at, like, our liquid handling business in China at the moment, it's actually growing. It's growing recently very well, you know, and what we do, like a lot of other things in China, And as we have on-site R&D capabilities to also go after. Some of these solutions that are also important for the local market when it comes to liquid handling. And so it's been actually a very good story for us. And it's a great part of how we think about M&A in general. It's been probably 25 years since we've acquired Reynon, but the capabilities we've developed globally since we've acquired Reynon has been really impressive. And China's, I think, a very important part of that story. And I'd say, too, the last thing on liquid handling is it's neat to see how many new products. It's another example of where we have a lot of new products coming out in the market. You've probably heard a few of these examples, and they're very differentiated.
Yeah, and to your point, the results. Kind of lay bare the fact that whatever competitive pressures you are seeing seemingly are manageable. I mean, the reigning business has quite honestly grown faster than I would think a pipette business might in a lot of historical periods there. So I understand what you're saying. Okay, maybe just, you know, we're getting down to it here. So I want to make sure I touch on the LRP, which you updated at the investor day. The idea is kind of for like six plus percent organic growth, 100 basis points of out margin expansion, and then... That can drive mid-teens EPS growth. On the 6% organic, so that's 200 basis points of pricing, roughly, and 400 basis points of volume. If you kind of divide the business into the lab side and the industrial side, what would be the expectation going forward for the makeup of those two components?
Yeah, so on the lab side, we would expect to do, you know, probably high single digit, and then on the industrial side, there's maybe two pieces, right? There's the core industrial side, which would be around corporate average, and then the product inspection side below corporate average.
Okay. And then on the op-margin side... One of the questions that I also get on Mettler is just where do the margin opportunities continue to come from for this company? I mean, it's just a factual statement that your out margin expansion has over the years been above average. How do those opportunities for the next three to five years look different or the same as they have for, I don't know, the last five to ten?
Yeah, I mean, I think historically we've always been, I feel very good about our history in terms of expanding margins. I think the last, you know, three or four years have been more challenging, just given the lack of volume we've seen in the business or just the industry. But I think despite that, and despite all the headwinds that we've had with... Topics like tariffs and all these other things. I feel actually quite good about our ability to deliver what we've delivered in margins in recent years. Going forward, it's very much going to be about getting that volume growth back. And, you know, our incremental margins are very good, right? You can see it kind of in our gross margin. And so if we kind of get, once we get the volumes going, our incrementals will really help out a lot. But we have a lot of levers to get there, too. Like, you know, I think the businesses that are going to grow the fastest in the future, according to our expectations, have higher margins. But we also, you know, the way that we invest in innovation resonates also in our margin, right? Like, if you can just, you know, if you're creating, enhancing that value proposition for your customer, there's going to just be a more natural willingness to pay, you know, for a product. I think we feel very good about our value proposition and our pricing program, and then we take that and we can reinvest in the business. We can reinvest in innovation for the future. We talked a lot about Stern Drive at the Investor Day. That's obviously another lever. But then this whole Blue Ocean program and what it does and how we use AI internally, it's just going to make us increasingly more productive as an organization. So I feel like there's a lot of levers here, and I think we understand the playbook. Each year it will be a little bit different, but I think when we step back, we know what we've got to do, and I think we have, most importantly, the culture of continuous improvement to kind of go after it.
Last question for you on that point. Is it correct to think that 4% to 5% organic growth is the point at which the leverage really starts to show up in the model?
Yeah, yeah, I think that's like, I think that's right. I think below that, you know, I mean, you've seen over the last few years what it could look like in different scenarios.
Okay. Okay, Sean, it is always great to see you. I really appreciate you coming during a busy period.
Yeah, thanks for hosting us. Great to see you, too. Thank you.